GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

GSK PLC GSK shares rose 2.17% to £14.35 Wednesday, on what proved to be an all-around positive trading session for the stock ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...